tbResList Print — NIV nivolumab

Filters: qv=22, qv2=%, rfv=%

Product

NIV nivolumab
Features: Immunomodulatory antibodies
Description: <b>Two</b> different inhibitory pathways that block antitumor T cell responses. <br>

Pathway results for Effect on Cancer / Diseased Cells

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 3,  
Total Targets: 2

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2025Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D WolchokPMC12080919https://pubmed.ncbi.nlm.nih.gov/39282897/0
2025Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.Sato RPMC11910964https://europepmc.org/article/pmc/pmc119109640
2026Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialT K Choueiri41786248https://pubmed.ncbi.nlm.nih.gov/41786248/0